Search
Now showing items 31-40 of 68
Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients
(2021-06)
This is the accepted manuscript of an article published online:
1. ACTRIMS Forum 2021 – Poster Presentations. Multiple Sclerosis Journal. 2021;27(1_suppl):15-122. doi:10.1177/13524585211015908
Highly effective disease-modifying treatment as initial MS therapy.
(2021-06-01)
PURPOSE OF REVIEW: Using highly effective (HE) compounds right from the beginning of disease-modifying immunotherapy (DMT) in people with multiple sclerosis (pwMS) has gained popularity among clinicians and pwMS alike. We ...
Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS)
(2020-12)
Meeting abstract P0196 from MSVirtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13, 2020
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
(2020-06-08)
OBJECTIVE: Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion ...